ClinicalTrials.gg
RecruitingNCT06081426Updated Nov 12, 2026

Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

An interventional study of Non-ketogenic Diet and Ketogenic Diet in Bipolar Disorder, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Bipolar Disorder by University of Pittsburgh — 1 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · University of Pittsburgh.

Planned enrollment
5th of 19
107 · median 53
Started
2024
the only one that year
No phase
13 of 22
1 open now
Registered
21st of 22
by date

Among the 22 studies in Bipolar Disorder by University of Pittsburgh, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 21st registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

1 of the 22 studies in Bipolar Disorder by University of Pittsburgh is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Bipolar Disorder by University of Pittsburgh, or all of them as a file.
02

Study summary

The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).

Read the detailed description

The investigators hypothesize that a ketogenic diet will enhance levels of the ketone body β-Hydroxybutyrate (beta OHB), resulting in reduced mania/hypomania severity and predisposition to mania/hypomania in individuals with BD. To test this hypothesis in depth, the investigators will use a novel, multidisciplinary mechanistic study using multimodal neuroimaging, peripheral markers of mitochondrial metabolism, and participant-derived induced pluripotent stem cell (iPSC)-derived organoids.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Ketogenic Diet
  • Magnetic Resonance Imaging
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants:

  • 18-40 years of age
  • Not following a ketogenic diet

BD hypomanic group (n=30):

  • Meeting sex proportion: 50% female
  • Meeting diagnosis proportion: 50:50% Bipolar I: Bipolar II (BDI:II) ( 5; DSM-5)
  • Score greater than 10 on the Young Mania Rating Scale score(YMRS)
  • BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
  • Has a primary care provider (if enrolled in ketogenic diet phase)

BD euthymic group (n=30):

  • Meeting sex proportion: 50% female
  • Meeting diagnosis proportion: 50:50% BDI:II (DSM-5)
  • Score less than or equal to 10 on YMRS
  • BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
  • Has a primary care provider (if enrolled in ketogenic diet phase)

Healthy Control (HC) Group (n=30):

  • Sex matched with BD groups
  • No psychiatric history

Exclusion criteria

Exclusion Criteria:

All participants:

  • Not between 18-40 years of age
  • History of head injury, neurological, pervasive developmental disorder (e.g. autism), systemic medical disease and treatment (medical records, participant report)
  • score (cognitive state) \<24
  • Premorbid National Adult Reading Test Intelligent Quotient (NAART IQ) estimate\<85
  • Visual disturbance: \<20/40 Snellen visual acuity
  • History of alcohol/substance use disorder (SUD; all substances, including nicotine), and/or illicit substance use (except cannabis) over the last 6 months (SCID-5). Note: lifetime/present cannabis use (at non-abuse (\<3 times in the past month) and non SUD levels) will be allowed, given its common usage in BD and young adults. Cannabis SUD over the last 6 months will not be allowed. Urine tests on scan days will exclude current illicit substance use (except cannabis). Salivary alcohol tests on scan days will exclude intoxicated individuals
  • MRI exclusion: metallic objects, e.g., surgical implants; claustrophobia; positive pregnancy test for females or self-report pregnancy
  • Unable to understand English
  • Conditions related to the pancreas, liver, thyroid or gallbladder.
  • Taking anticoagulants and/or those with blood dyscrasias (illnesses) who have coagulation disorders (eg, hemophilia) because of the ketomojo finger stick blood tests
  • Scoring 3 or higher on positive symptom factor questions on the Positive and Negative Syndrome Scale (PANSS) questionnaire (indicative of psychotic symptoms)
  • Currently following a ketogenic diet
  • Head circumference larger than 24 inches (62cm) and/or chest circumference larger than 55 inches (139 cm)
  • Taken medications for diabetes and weight loss (e.g., Wegovy, Orlistat) in the past month

BD hypomanic group:

  • Must be meeting sex proportions: not 50% female
  • Must be meeting diagnosis proportions: not 50:50% BDI:II ()
  • Diagnosis of BD in a manic or euthymic episode
  • Score 10 or lower on the Young Mania Rating Scale score(YMRS)
  • Using psychotropic medications other than those allowed in inclusion criteria
  • Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
  • Does not have a primary care provider (if enrolled in ketogenic diet phase)

BD euthymic group:

  • Not meeting sex proportion: not 50% female
  • Not meeting diagnosis proportion: not 50:50% BDI:II
  • Diagnosis of BD in a depressive, hypomanic, or manic episode
  • Score greater than 10 on YMRS
  • Using psychotropic medications other than those allowed in inclusion criteria
  • Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
  • Does not have a primary care provider (if enrolled in ketogenic diet phase)

Healthy Control (HC) Group

  • Not sex-matched with BD groups
  • Has psychiatric history
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
107 participants (estimated)

Study arms

  • Experimental
    1st phase Non-ketogenic Diet / 2nd phase Ketogenic Diet

    Participants with Bipolar Disorder will consume a non-ketogenic diet for the first phase of the study and then a ketogenic diet for the second phase of the study

    Other: Non-ketogenic Diet · Other: Ketogenic Diet

  • Experimental
    1st phase Ketogenic Diet / 2nd phase Non-ketogenic Diet

    Participants with Bipolar Disorder will consume a ketogenic diet for the first phase of the study and then a non-ketogenic diet for the second phase of the study

    Other: Non-ketogenic Diet · Other: Ketogenic Diet

  • Other
    No diet

    Participants without Bipolar Disorder will not participate in the diet phases of the study

    Other: No diet

Interventions

  • OtherNon-ketogenic Diet

    Consuming a non-ketogenic diet

  • OtherKetogenic Diet

    Consuming a ketogenic diet

  • OtherNo diet

    Participants without Bipolar Disorder will not participate in the diet phases of the study

06

What researchers measure

Primary outcomes

  1. Blood oxygen level-dependent (BOLD) signal at Scan 1

    The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

    Time frame: Baseline Scan 1 (all participants)

  2. Blood oxygen level-dependent (BOLD) signal at Scan 2

    The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  3. Blood oxygen level-dependent (BOLD) signal at Scan 3

    The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  4. Manic symptoms at Scan 1

    The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

    Time frame: Baseline Scan 1 (all participants)

  5. Manic symptoms at Scan 2

    The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

    Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  6. Manic symptoms at Scan 3

    The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

    Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  7. Fasting Glucose at Baseline

    Fasting glucose blood levels

    Time frame: Baseline (all participants)

  8. Fasting lipids at Baseline

    Fasting lipid blood levels

    Time frame: Baseline (all participants)

  9. Fasting hepatic function panel at Baseline: total protein

    Fasting levels of total protein in the blood

    Time frame: Baseline (all participants)

  10. Fasting hepatic function panel at Baseline: albumin

    Fasting levels of albumin in the blood

    Time frame: Baseline (all participants)

  11. Fasting hepatic function panel at Baseline: bilirubin

    Fasting levels of bilirubin in the blood

    Time frame: Baseline (all participants)

  12. Fasting hepatic function panel at Baseline: liver enzyme

    Fasting levels of liver enzyme in the blood

    Time frame: Baseline (all participants)

  13. Fasting Glucose at halfway point through first dietary phase

    Fasting glucose blood levels

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  14. Fasting lipids at halfway point through first dietary phase

    Fasting lipid blood levels

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  15. Fasting hepatic function at halfway point through first dietary phase: total protein

    Fasting levels of total protein in the blood

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  16. Fasting hepatic function at halfway point through first dietary phase: albumin

    Fasting levels of albumin in the blood

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  17. Fasting hepatic function at halfway point through first dietary phase: bilirubin

    Fasting levels of bilirubin in the blood

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  18. Fasting hepatic function at halfway point through first dietary phase: liver enzyme

    Fasting levels of liver enzyme in the blood

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  19. Fasting Glucose at end of first dietary phase

    Fasting glucose blood levels

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  20. Fasting lipids at end of first dietary phase

    Fasting lipid blood levels

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  21. Fasting hepatic function at end of first dietary phase: total protein

    Fasting levels of total protein in the blood

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  22. Fasting hepatic function at end of first dietary phase: albumin

    Fasting levels of albumin in the blood

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  23. Fasting hepatic function at end of first dietary phase: bilirubin

    Fasting levels of bilirubin in the blood

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  24. Fasting hepatic function at end of first dietary phase: liver enzyme

    Fasting levels of liver enzyme in the blood

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  25. Fasting Glucose at halfway point through second dietary phase

    Fasting glucose blood levels

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  26. Fasting lipids at halfway point through second dietary phase

    Fasting lipid blood levels

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  27. Fasting hepatic function at halfway point through second dietary phase: total protein

    Fasting levels of total protein in the blood

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  28. Fasting hepatic function at halfway point through second dietary phase: albumin

    Fasting levels of albumin in the blood

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  29. Fasting hepatic function at halfway point through second dietary phase: bilirubin

    Fasting levels of bilirubin in the blood

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  30. Fasting hepatic function at halfway point through second dietary phase: liver enzyme

    Fasting levels of liver enzyme in the blood

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

  31. Fasting Glucose at end of second dietary phase

    Fasting glucose blood levels

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  32. Fasting lipids at end of second dietary phase

    Fasting lipids blood levels

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  33. Fasting hepatic function at end of second dietary phase: total protein

    Fasting levels of total protein in the blood

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  34. Fasting hepatic function at end of second dietary phase: albumin

    Fasting levels of albumin in the blood

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  35. Fasting hepatic function at end of second dietary phase: bilirubin

    Fasting levels of bilirubin in the blood

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  36. Fasting hepatic function at end of second dietary phase: liver enzyme

    Fasting levels of liver enzyme in the blood

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  37. Gamma-aminobutyric acid (GABA) at Baseline

    Gamma-aminobutyric acid (GABA) concentrations in the brain

    Time frame: Baseline Scan 1 (all participants)

  38. Glutamate at Baseline

    Glutamate concentrations in the brain

    Time frame: Baseline Scan 1 (all participants)

  39. Lactate at Baseline

    Lactate concentrations in the brain

    Time frame: Baseline Scan 1 (all participants)

  40. Gamma-aminobutyric acid (GABA) at end of first dietary phase

    Gamma-aminobutyric acid (GABA) concentrations in the brain

    Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  41. Glutamate at end of first dietary phase

    Glutamate concentrations in the brain

    Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  42. Lactate at end of first dietary phase

    Lactate concentrations in the brain

    Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  43. Gamma-aminobutyric acid (GABA) at end of second dietary phase

    Gamma-aminobutyric acid (GABA) concentrations in the brain

    Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  44. Glutamate at end of second dietary phase

    Glutamate concentrations in the brain

    Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  45. Lactate at end of second dietary phase

    Lactate concentrations in the brain

    Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Secondary outcomes

  1. Average total sleep time during Ketogenic vs Normal diet

    Total sleep time will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home.

    Time frame: Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals

  2. Average rest-activity rhythm interdaily stability during Ketogenic vs Normal diet

    Rest-activity rhythm interdaily stability will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home

    Time frame: Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.

  3. Ecological momentary assessments (EMA) during the first dietary phase: Mood monitoring

    Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood

    Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  4. Ecological momentary assessments (EMA) during the first dietary phase: Energy monitoring

    Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy

    Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  5. Ecological momentary assessments (EMA) during the first dietary phase: Suicidality monitoring

    Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans

    Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  6. Ecological momentary assessments (EMA) during the second dietary phase: Mood monitoring

    Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood

    Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  7. Ecological momentary assessments (EMA) during the second dietary phase: Energy monitoring

    Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy

    Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

  8. Ecological momentary assessments (EMA) during the second dietary phase: Suicidality monitoring

    Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans

    Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Informed consent will be collected from study participants that allows for broad sharing of participants' de-identified data. Data transfer procedures will be in accordance with all Institutional Review Board guidelines and federal regulations including HIPAA (Health Insurance Portability and Accountability Act of 1996).

Time frame: The principal investigators (PIs) reserve the right to publish on the stated aims in a timely manner. Data will be available for addressing other research questions (i.e. which are not described in funded/pending grants) as soon as the data have been checked for accuracy (a period which will be no later than one year after the completion of each assessment). After the study has ended, the study investigators will continue to test the stated aims, but will also continue to solicit collaborations with outside researchers and to consider data requests in a timely manner.

Access criteria: Outside investigators must submit a 1)proposal of the study aims, hypotheses, variables/constructs, analytic approach, and estimated duration of the proposed research; 2)resume, qualifications, source of financial support, and conflict of interest statement; 3)sign a data-sharing agreement and confidentiality statement that stipulates using the data for the stated research purposes only, securing the data using appropriate computer technology, not manipulating the data in order to identify participants, acknowledging the grant that supported data collection and management in publications/presentations, and destroying or returning the data after analyses are complete; 4)obtain approval from their Institutional Review Board, and along with other staff members who have access to the data, submit certificates of the University of Pittsburgh Education and Certification Program in Research Practice Fundamentals or provide written documentation of similar human subjects protection training.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 41 months is above that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2027 → Jun 2027 and completion Jan 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Oct 13, 2023
StartActual
Jan 12, 2024
Primary completionEst.
Jun 2027was Jan 2027
CompletionEst.
Jun 2027was Jan 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2027→Jun 2027
Nov 12, 2026
Study completion
Jan 2027→Jun 2027
Nov 12, 2026
Eligibility
2 inclusion criteria added; 3 exclusion criteria added
What changed in the criteria
Inclusion criteria
  • AddedHas a primary care provider (if enrolled in ketogenic diet phase)
  • AddedHas a primary care provider (if enrolled in ketogenic diet phase)
Exclusion criteria
  • AddedTaken medications for diabetes and weight loss (e.g., Wegovy, Orlistat) in the past month
  • AddedDoes not have a primary care provider (if enrolled in ketogenic diet phase)
  • AddedDoes not have a primary care provider (if enrolled in ketogenic diet phase)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jan 2027→Jun 2027
    Study completion Jan 2027→Jun 2027
    Eligibility 2 inclusion criteria added; 3 exclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • AddedHas a primary care provider (if enrolled in ketogenic diet phase)
    • AddedHas a primary care provider (if enrolled in ketogenic diet phase)
    Exclusion criteria
    • AddedTaken medications for diabetes and weight loss (e.g., Wegovy, Orlistat) in the past month
    • AddedDoes not have a primary care provider (if enrolled in ketogenic diet phase)
    • AddedDoes not have a primary care provider (if enrolled in ketogenic diet phase)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06081426
Collaborators
Baszucki Brain Research Fund
Responsible party
Mary Phillips, MD MD (Cantab) (Professor, University of Pittsburgh) — Principal investigator
First posted
Oct 13, 2023
Start date
Jan 12, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Jill Morris-Tillman
Contact
morristillmanje@upmc.edu
412-383-8206
Mary Phillips, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion